Calls for papers
-
Aradigm has announced the appointment of Juergen Froehlich as Chief Medical Officer. Froehlich is formerly Head of Regulatory Affairs at Vertex Pharmaceuticals where he was responsible for regulatory submissions for Kalydeco. Both of Aradigm’s inhaled… Read more . . .
-
Particle Sciences has announced that it has been awarded a contract for development of an intranasal progesterone formulation for the treatment of traumatic brain injury by BHR Pharma, a subsidiary of Besins Healthcare. Besins announced… Read more . . .
-
Dutch pharmaceutical compliance specialist Timer Designs has announced the launch of the Compliance Cradle for Advair/Seretide Diskus inhalers. The device monitors the presence of the Diskus and alerts patients to take a dose of the… Read more . . .
-
GSK and Theravance have announced that the European Commission has approved Relvar Ellipta fluticasone furoate/vilanterol (FF/VI) DPI for the treatment of asthma for patients whose disease is not adequately controlled by ICS plus an as-needed… Read more . . .
-
Intertek, which recently acquired Melbourn Scientific, has announced the launch of development, formulation and characterization service for both large and small molecule inhaled and nasal drug products. The acquisition of Melbourn Scientific was announced in… Read more . . .
-
Express Scripts, a pharmacy benefit manager (PBM) that administers prescription drug programs for more than 100 million Americans, has announced the exclusion of more than a dozen popular OINDPs from its 2014 national preferred drug… Read more . . .
-
The United States Patent and Trademark Office (USPTO) has issued Civitas Therapeutics US Patent No. 8,545,878, with an expiration date of November 16, 2032, for a patent titled “Capsules containing high doses of levodopa for… Read more . . .
-
Bend Research has announced a $20+ million expansion of its commercial spray drying capacity, including a new commercial manufacturing facility with two PSD spray dryer process trains. The company expects completion and validation of the… Read more . . .
-
In a November 5, 2013 interview on CNBC, Acorda CEO Ron Cohen announced that the company has filed a regulatory application to the FDA for its diazepam nasal spray for the treatment of epilepsy. Acorda… Read more . . .
-
Novartis has announced that “it will initiate consultation on proposals to close” its respiratory R&D center in Horsham, UK. According to Novartis, the potential closing will affect “up to 371 roles” at the site, plus… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA